Korro Bio Inc. logo

Korro Bio Inc.

KRRO | NASDAQ
Chart Builder DCF Calculator
$9.98
-$0.04 (-0.40%)
At close: Sep 21, 2026, 4:00 PM ET
$10
+$0.02 (+0.20%)
Pre-market: Sep 22, 2026, 8:24 AM ET

Company Profile

Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.

Key Executives

Name Position
Ram Aiyar Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director
Stephanie Engels Chief People Officer
Todd Chappell Chief Operating Officer
Andrew Fraley Co-Founder & Advisor
Gaozhong Zhu SVP of Chemistry, Manufacturing and Controls & Technical Operations
Jean-Francois Formela Co-Founder & Director
Jeffrey Cerio Senior Vice President, General Counsel & Corporate Secretary
Joshua Rosenthal Co-Founder & Advisor
Loic Vincent Chief Scientific Officer
Oliver Dolan Senior Vice President of Finance & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Aug 28, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 19, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 05, 2026 4 Filing
Aug 04, 2026 SC 13D/A [Amend] Filing
View All SEC Filings
Korro Bio Inc.
Korro Bio Inc. logo
Country United States
IPO Date Oct 2, 2019
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Ram Aiyar

Contact Details

60 First Street Cambridge, Massachusetts 02141 United States

Stock Details

Ticker Symbol KRRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001703647
CUSIP Number 500946108
ISIN Number US5009461089
SIC Code 2834

© 2026 bestshares.com. All rights reserved.